Cargando…
Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma
BACKGROUND: The need for new therapies for cholangiocarcinoma is highlighted by their poor prognosis and refractoriness to chemotherapy. Increased production of Interleukin-6 promotes cholangiocarcinoma growth and contributes to chemoresistance by activating cell survival mechanisms. We sought to id...
Autores principales: | Braconi, Chiara, Swenson, Erica, Kogure, Takayuki, Huang, Nianyuan, Patel, Tushar |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002961/ https://www.ncbi.nlm.nih.gov/pubmed/21179572 http://dx.doi.org/10.1371/journal.pone.0015195 |
Ejemplares similares
-
Hepatic miR-29ab1 expression modulates chronic hepatic injury
por: Kogure, Takayuki, et al.
Publicado: (2012) -
Emerging molecular targets and therapy for cholangiocarcinoma
por: Kayhanian, Hamzeh, et al.
Publicado: (2017) -
Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids
por: Amato, Francesco, et al.
Publicado: (2020) -
Heterogeneity of Cholangiocarcinoma Immune Biology
por: Vita, Francesca, et al.
Publicado: (2023) -
Extracellular RNA transfer from non‐malignant human cholangiocytes can promote cholangiocarcinoma growth
por: Ota, Yu, et al.
Publicado: (2021)